Review article: current and future treatment approaches for IBS with constipation

Liu, Joy; Brenner, Darren M.

doi:10.1111/apt.16607

Cited by 1 publication

(1 citation statement)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approximately one-third of these patients are diagnosed with irritable bowel syndrome with constipation(IBS-C), a subtype of IBS. The therapeutic objectives primarily focus on alleviating symptoms, improving the patients’ quality of life, and reinstating their normal social functioning rather than eradicating the disease [ 3 , 4 ]. Several guidelines and consensus statements have recommended the use of antidepressants, laxatives, prokinetics, and probiotics for the treatment of IBS-C patients.…”

Section: Introductionmentioning

confidence: 99%

The gut microbiota participates in the effect of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C): a multicenter, prospective, pre-post study

Zhou,

Wei,

Zhou

et al. 2024

J Transl Med

View full text Add to dashboard Cite

Background Interindividual variation characterizes the relief experienced by constipation-predominant irritable bowel syndrome (IBS-C) patients following linaclotide treatment. Complex bidirectional interactions occur between the gut microbiota and various clinical drugs. To date, no established evidence has elucidated the interactions between the gut microbiota and linaclotide. We aimed to explore the impact of linaclotide on the gut microbiota and identify critical bacterial genera that might participate in linaclotide efficacy. Methods IBS-C patients were administered a daily linaclotide dose of 290 µg over six weeks, and their symptoms were then recorded during a four-week posttreatment observational period. Pre- and posttreatment fecal samples were collected for 16S rRNA sequencing to assess alterations in the gut microbiota composition. Additionally, targeted metabolomics analysis was performed for the measurement of short-chain fatty acid (SCFA) concentrations. Results Approximately 43.3% of patients met the FDA responder endpoint after taking linaclotide for 6 weeks, and 85% of patients reported some relief from abdominal pain and constipation. Linaclotide considerably modified the gut microbiome and SCFA metabolism. Notably, the higher efficacy of linaclotide was associated with enrichment of the Blautia genus, and the abundance of Blautia after linaclotide treatment was higher than that in healthy volunteers. Intriguingly, a positive correlation was found for the Blautia abundance and SCFA concentrations with improvements in clinical symptoms among IBS-C patients. Conclusion The gut microbiota, especially the genus Blautia, may serve as a significant predictive microbe for symptom relief in IBS-C patients receiving linaclotide treatment. Trial registration: This trial was registered with the Chinese Clinical Trial Registry (Chictr.org.cn, ChiCTR1900027934).

show abstract

Section: Introductionmentioning

confidence: 99%